Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 8/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6397655 | 0.75 | SLC10A2 (0.57) | SLC10A2 | |
| SCHEMBL6827627 | 0.72 | SLC10A2 (0.58) | SLC10A2 | |
| SCHEMBL6201735 | 0.72 | SLC10A2 (0.58) | SLC10A2 | |
| SCHEMBL6823538 | 0.72 | SLC10A2 (0.58) | SLC10A2 | |
| SCHEMBL27453871 | 0.72 | SIGMAR1 (0.33) | KDM1AELANE | |
| SCHEMBL8028186 | 0.71 | KDM4E (0.36) | ELANEMAPT | |
| SCHEMBL8382184 | 0.71 | SLC10A2 (0.58) | SLC10A2 | |
| SCHEMBL8574028 | 0.71 | SLC10A2 (0.39) | SLC10A2KDM1AMAOAMAOB | |
| SCHEMBL8382182 | 0.71 | SLC10A2 (0.58) | SLC10A2 | |
| SCHEMBL8204368 | 0.71 | SLC10A2 (0.39) | SLC10A2KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943189-B2 | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG CO-A reductase inhibitors | G.D. SEARLE & CO. (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040176438-A1 | Novel mono- and di-fluorinated beozothiepine copmunds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake | G.D. SEARLE, LLC | 2004-09-09 | — | — | US | disclosed |
| US-6784201-B2 | FOR PROPHYLAXIS AND TREATMENT OF HYPERLIPIDEMIC CONDITIONS SUCH AS THOSE ASSOCIATED WITH ATHEROSCLEROSIS OR HYPERCHOLESTEROLEMIA | G.D. SEARLE & COMPANY | 2004-08-31 | — | — | US | disclosed |
| US-20040157915-A1 | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors | G.D. SEARLE & CO. (US) | 2004-08-12 | — | — | US | disclosed |
| EP-1440972-A1 | Novel benzothiepines having pharmaceutical activity. | G.D. Searle & Co. (US) | 2004-07-28 | — | — | EP | disclosed |
| US-6740663-B2 | ANTIHYPERLIPIDEMIC AGENTS | G.D. SEARLE, LLC | 2004-05-25 | — | — | US | disclosed |
| US-20040067872-A1 | Novel mono- and di-fluorinated benzothiepine compouds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake | G.D. SEARLE, LLC (US) | 2004-04-08 | — | — | US | disclosed |
| US-20040014803-A1 | Novel benzothiepines having activity as inhibitors of lleal bile acid transport and taurocholate uptake | G.D. SEARLE & CO. (US) | 2004-01-22 | — | — | US | disclosed |
| US-6642268-B2 | Treatment of hyperlipidemic conditions such as those associated with atherosclerosis or hypercholesterolemia, in mammals. | G.D. SEARLE & CO. | 2003-11-04 | — | — | US | disclosed |
| US-20030171426-A1 | Combination therapy employing ileal bile acid transport inhibiting benzothiepiens and HMG Co-A reductase inhibitors | G.D. SEARLE & CO. (US) | 2003-09-11 | — | — | US | disclosed |
| US-20020013476-A1 | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake | G.D. SEARLE & CO. | 2002-01-31 | — | — | US | disclosed |
| US-6268392-B1 | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors | G. D. SEARLE & CO. | 2001-07-31 | — | — | US | disclosed |
| US-6262277-B1 | IN MEDICINE FOR PROPHYLAXIS AND THERAPY OF HYPERLIPIDEMIC CONDITIONS SUCH AS THOSE ASSOCIATED WITH ATHEROSCLEROSIS OR HYPERCHOLESTEROLEMIA, IN MAMMALS | G.D. SEARLE AND COMPANY | 2001-07-17 | — | — | US | disclosed |
| EP-0781278-B1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | MONSANTO CO (US) | 2001-03-14 | — | — | EP | disclosed |
| US-6107494-A | FOR TREATMENT OF HYPERLIPIDEMIC CONDITIONS SUCH AS THOSE ASSOCIATED WITH ATHEROSCLEROSIS OR HYPERCHOLESTEROLEMIA, IN MAMMALS | G.D. SEARLE AND COMPANY (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0971744-A2 | COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-01-19 | — | — | EP | disclosed |
| US-5994391-A | HYPERLIPEMIC AGENTS; ANTICHOLESTEROL AGENTS | G.D. SEARLE AND COMPANY (US) | 1999-11-30 | — | — | US | disclosed |
| EP-0888333-A1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | G.D. Searle & Co. (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1998040375-A2 | COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-09-17 | — | — | WO | disclosed |
| WO-1997033882-A1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | G.D. SEARLE AND CO. (US) | 1997-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013476-A1 | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake | SLC10A2, SLC10A1, ABCB11 | SLC10A2 1/4885KDM1A 4667/4885MAOA 2864/4885 |
| US-20040157915-A1 | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors | SLC10A2, SLC10A1, HMGCR | SLC10A2 1/4885KDM1A 3907/4885MAOA 1327/4885 |
| US-20030171426-A1 | Combination therapy employing ileal bile acid transport inhibiting benzothiepiens and HMG Co-A reductase inhibitors | SLC10A2, SLC10A1, HMGCR | SLC10A2 1/4885KDM1A 3972/4885MAOA 1914/4885 |
| US-20040067872-A1 | Novel mono- and di-fluorinated benzothiepine compouds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885KDM1A 4759/4885MAOA 2404/4885 |
| US-20040176438-A1 | Novel mono- and di-fluorinated beozothiepine copmunds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885KDM1A 4787/4885MAOA 3145/4885 |
| US-20040014803-A1 | Novel benzothiepines having activity as inhibitors of lleal bile acid transport and taurocholate uptake | SLC10A1, SLC10A2, NR1H4 | SLC10A2 2/4885KDM1A 4411/4885MAOA 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.